For instance, some potential therapeutic targets for TB-IRIS may include IL-6, TNF-α and IL-18; while potential therapeutic targets for KS-IRIS may include HHV-8 LANA, IL-6, proangiogenic factors, and others. This evidence concerns the gene IL6 and Kaposi's sarcoma.